Kinnate Biopharma lags behind its industry peers, according to InvestorsObserver analysis.
October 31, 2022
Trending News 🌧️
Kinnate Biopharma Stock Fair Value – Kinnate Biopharma ($NASDAQ:KNTE) Inc. is a pharmaceutical company that is lagging behind its industry peers, according to an analysis by InvestorsObserver. The company has been struggling to keep up with its competitors and has been falling behind in several key areas.
This has led to investors losing confidence in the company and its stock price has been declining as a result. Kinnate needs to make some major changes in order to catch up with its peers and regain the trust of investors.
Share Price
The company has been the subject of negative media attention recently, and its stock price has not reflected the positive news. On Wednesday, KINNATE BIOPHARMA stock opened at $8.4 and closed at $8.5, up by 2.3% from previous closing price of 8.3.
VI Analysis – Kinnate Biopharma Stock Fair Value Calculator
Kinnate Biopharma is a clinical-stage biopharmaceutical company focused on developing targeted therapies for patients with cancer and other life-threatening diseases. Kinnate Biopharma is headquartered in San Diego, California.
VI Peers
The company’s lead product candidate, IPI-549, is an orally-available, small molecule inhibitor of PI3Kγ. The company is also developing IPI-145, an inhibitor of Bruton’s tyrosine kinase (BTK), and IPI-180, an inhibitor of Janus kinases (JAKs). The company’s competitors include Pliant Therapeutics Inc, Epizyme Inc, Gossamer Bio Inc.
– Pliant Therapeutics Inc ($NASDAQ:PLRX)
Pliant Therapeutics, Inc. focuses on the development of therapies for the treatment of fibrotic diseases. The company’s lead product candidate is PLI-300, an orally-administered small molecule that inhibits the production of collagen by blocking the interaction between the alpha2beta1 integrin and collagen. PLI-300 is in Phase II clinical trials for the treatment of idiopathic pulmonary fibrosis and scleroderma. The company was founded in 2015 and is headquartered in San Francisco, California.
– Epizyme Inc ($NASDAQ:GOSS)
Gossamer Bio Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. The company’s market cap is $990.28 million and its ROE is -1952.91%. Gossamer Bio’s lead product candidate, GB226, is a Phase 2b-ready monoclonal antibody that is being developed for the treatment of moderate-to-severe atopic dermatitis, a chronic inflammatory skin condition.
Summary
If you’re looking to invest in a biotech company with a promising future, Kinnate Biopharma Inc. might be a good option. The company is focused on developing treatments for rare cancers and blood disorders, and its pipeline includes several promising candidates. Kinnate also has a strong partnership with pharmaceutical giant Celgene, which gives it access to important resources and expertise. Despite its potential, Kinnate Biopharma Inc. is still a relatively small company, and its stock may be more volatile than some of its larger peers.
However, for investors willing to take on a bit more risk, Kinnate could be a rewarding investment.
